2020
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.
Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyReasonable treatment optionMore side effectsLung cancer patientsCancer care settingsPatient-centered careTreatment decision processNational Quality ForumInhibitor therapyPatient-centric careCancer patientsTreatment optionsTreatment choicePost-intervention interviewsPatientsSide effectsPractice settingsQuality ForumSDM skillsHealthcare decisionsCareSDM processGreater improvementCliniciansTeam members
2019
Nursing Considerations for Patients Treated with Targeted Therapies
Goodwin K, Davies M. Nursing Considerations for Patients Treated with Targeted Therapies. 2019, 105-120. DOI: 10.1007/978-3-030-16550-5_9.Peer-Reviewed Original ResearchThe Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer
Andrews S, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. 2019, 65-84. DOI: 10.1007/978-3-030-16550-5_7.Peer-Reviewed Original Research
2008
Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC)
Shah M, Hotchkiss S, Shanley J, Davies M, Ferencz T, Syrigos K, Syrigos K, Saif M. Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2008, 26: 15092-15092. DOI: 10.1200/jco.2008.26.15_suppl.15092.Peer-Reviewed Original Research
2004
A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer
Murren J, Gerson S, Kummar S, Davies M, Remick S, Chu E, Karsten V, Sznol M. A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer. Journal Of Clinical Oncology 2004, 22: 2060-2060. DOI: 10.1200/jco.2004.22.14_suppl.2060.Peer-Reviewed Original ResearchA Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer
Murren J, Gerson S, Kummar S, Davies M, Remick S, Chu E, Karsten V, Sznol M. A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer. Journal Of Clinical Oncology 2004, 22: 2060-2060. DOI: 10.1200/jco.2004.22.90140.2060.Peer-Reviewed Original Research